Michael Tarnok was appointed Director of Ionetix Corp / DE /, effective May 18, 2026. As of November 6, 2026, Ionetix Corp / DE / has reported 3 leadership change filings to the SEC under Item 5.02 of Form 8-K, from April 16, 2026 to October 29, 2026, naming 2 appointments (Form 8-K, May 20, 2026).
30 companies changed executives this week.
Companies that just changed executives, and the new executive. Before you unlock: the company, the change and what is inside. After: the executive named with their role, how to reach the company, and a person's email only when we found one.
| John Hancock Comvest Private Income Fund | named a new Chief Financial Officer | |
| Bain Capital Specialty Finance, Inc. | named a new Director | |
| Azora Therapeutics, Inc. (DE) | named a new Director | |
| LASE Corp. | named a new Director | |
| Century Communities, Inc. | named a new Executive Chairman |
Sell to companies like Ionetix Corp / DE /? Enter your website and see 10 with a filed reason to buy from you this month. Free.
Opens in a new tab. No signup.
Key facts
- · In / out: Reported · Person: not named in the filing · 8-K, 2026-10-29
- · In / out: In · Person: Michael Tarnok · Role: Director · Effective: 2026-05-18 · 8-K, 2026-05-20
- · In / out: Reported · Person: not named in the filing · 8-K, 2026-04-16
Ionetix Corp / DE / reported changes in 3 filings among its directors and officers to the SEC on Form 8-K, Item 5.02, from 2026-04-16 to 2026-10-29. They name 2 people. Every row below is cited to the filing it comes from, and this page adds each new change as Ionetix Corp / DE / files it.
Also on the record for Ionetix Corp / DE /
| Date | Record | Figure | Our page | Source |
|---|---|---|---|---|
| July 24, 2026 | Stake report, Schedule 13G, by ELI LILLY & Co | 7.9% of the class | 5%+ stakes | Source |
| April 23, 2026 | Form D, private offering | $32.33M sold | Form D page | Source |
| April 20, 2026 | Stake report, Schedule 13D, by Shamrock Ionetix LLC | 7.2% of the class | 5%+ stakes | Source |
| April 20, 2026 | Stake report, Schedule 13G, by Ospraie Real Assets Fund LP | 19.9% of the class | 5%+ stakes | Source |
Selling to them or working with them? See who runs Ionetix Corp / DE / now and the warning signs.
Free to see. No signup.
Keep reading
More on Ionetix Corp / DE / and the records around it.
Ionetix Corp / DE / elsewhere on the record
- 5%+ stake filings Jul 2026
- Form D filing Apr 2026
- Who owns it
Companies that share a holder
- Ospraie Real Assets Fund LP also filed stake reports on 2 other companies: Sinda Ltd. (Aug 2026), Sunshine Silver Mining & Refining Co (Aug 2026)
- ELI LILLY & Co also filed stake reports on 5 other companies: TRex Bio, Inc. (Oct 2026), Scribe Therapeutics, Inc. (Jul 2026), ProQR Therapeutics N.V. (Jul 2026)
Watch Ionetix Corp / DE /
Get an email when Ionetix Corp / DE / files again: a new raise, a leadership change, a layoff or an IPO filing. One email first to confirm; nothing else until you click it. At most one a day, one click to stop. Free for up to 3 companies.
Want the whole picture on Ionetix Corp / DE /?
Example from a real report (our sample on Target): “Target eliminated approximately 1,800 corporate positions, with around 1,000 employees receiving layoff notices and the remainder accounted for by eliminating open roles.” Source: NBC News
A Full Report on Ionetix Corp / DE /: verified, sourced, every claim cited, ready in a few minutes. See pricing.
What the Full Report on Ionetix Corp / DE / covers
The Short Answer
Which Company This Is
What They Do, And How The Money Works
Who Runs It, And How To Reach Them
The Money: Funding, Valuation, Runway
Who Pays Them, And Who They Are Up Against
Warning Bells
Sources
7 cited sources found
Plus the sections for what you are deciding, which you pick after ordering.
A real finished report, first screen. Opens in a new tab.
Not ready to order yet? Keep this snapshot.
Sends this preview to you once; we won't add you to any list
Timeline
| Filed | In / out | Person | Role | Effective | Source |
|---|---|---|---|---|---|
| 2026-10-29 | Reported | not named in the filing | 8-K, 2026-10-29 | ||
| 2026-05-20 | In | Director | 2026-05-18 | 8-K, 2026-05-20 | |
| 2026-05-20 | In | Director | 8-K, 2026-05-20 | ||
| 2026-04-16 | Reported | not named in the filing | 8-K, 2026-04-16 |
Who leads Ionetix Corp / DE /, as last reported?
For each role that changed in the filings below, the most recent change reported. A role that did not change in these filings is not listed.
- Director: Kevin Cameron, appointed (filed 2026-05-20).
New leaders reset buying decisions — get the Full Report on Ionetix Corp / DE /: who runs it, how the money works and what to watch, every claim linked to its source.
Get the Full ReportFind people with the same kind of experience as the Director at Ionetix Corp / DE /, with the record behind each one.
Find candidates like Director at Ionetix Corp / DE /Every change, in the filing's words
Reported
The employment agreements also provide for full acceleration upon a qualifying termination in connection with or following a Change of Control (as defined in the employment agreements) and, subject to the continued-service conditions set forth in the employment agreements, immediately prior to a Change of Control in which awards are neither assumed nor substituted.
- Each option has an exercise price of $3.00 per share, which the Board determined to be the fair market value of a share of the Company's common stock on the grant date.
- Each option is subject to the 2026 Equity Plan and the applicable award agreement.
- Each option will vest as to 25% of the shares subject to the option on the first anniversary of the grant date and as to 1/36 th of the remaining shares monthly over the 36-month period thereafter, subject to the applicable named executive officer's continued service to the Company through each applicable vesting date, and expires 10 years from the grant date, subject to earlier termination in accordance with the 2026 Equity Plan and the applicable award agreement.
- Each option is also subject to the applicable employment agreement between Ionetix Radioisotopes, Inc. (formerly known as Ionetix Corporation) ("Radioisotopes"), the Company's wholly owned subsidiary, and such named executive officer dated April 1, 2026, which provides for full vesting acceleration upon an Involuntary Separation (as defined in the employment agreements), subject to the named executive officer's execution and non-revocation of a release of claims and return of company property.
Appointed: Michael Tarnok, Director, effective 2026-05-18
On May 15, 2026, the Board appointed Michael Tarnok to the Board as a Class II director, effective as of May 18, 2026.
Appointed: Kevin Cameron, Director
Increase to Whole Board; Appointment to Fill Vacancy On May 15, 2026, the Board increased the size of the Board from four to five members, and appointed Kevin Cameron, the Company's Chief Executive Officer, to the Board as a Class III director, effective immediately.
- - Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers Resignation of David Landskowsky On May 15, 2026, David Landskowsky tendered his resignation as a member of the board of directors ("Board") of Ionetix Corporation (the "Company"), effective as of May 15, 2026.
- Mr. Landskowsky's resignation was not the result of any disagreement with the Company on any matter relating to the Company's operations, policies, or practices.
- The compositions of the Audit Committee, the Compensation Committee, and the Nominating and Governance Committee are as follows: - Audit Committee: The Audit Committee consists of Gregory Martin, Michael Tarnok and Michael Stewart.
- Mr. Martin is the chair of the Audit Committee. - Compensation Committee: The Compensation Committee consists of Gregory Martin, Douglas Boothe and Michael Tarnok.
- Mr. Boothe is the chair of the Compensation Committee. - Nominating and Governance Committee: The Nominating and Governance Committee consists of Gregory Martin, Michael Tarnok, and Michael Stewart.
- Mr. Stewart is the chair of the Nominating and Governance Committee.
Reported
The information regarding departure and election of our directors and departure and appointment of our principal officers in connection with the Merger set forth in I tem 2.01, " Completion of Acquisition or Disposition of Assets - The Merger and Related Transactions - Departure and Appointment of Directors and Officers " is incorporated herein by reference.
Tools for this story
Each opens in a new tab, filled in for Ionetix Corp / DE /. With no account yet, you sign up free and land on the result.
Where this comes from
A public company must file a current report on Form 8-K with the SEC within four business days when a director leaves or is elected, or when its chief executive, chief financial, chief accounting or chief operating officer, or another named executive, departs or is appointed. That disclosure goes under Item 5.02 of the report.
Every change on this page is taken from one of those filings and quoted in the company's own words, with a link to the filing, so it can be checked at the source. Where a filing names the person, the role and the date a change takes effect, they are shown beside the quote. Where it does not, the quote stands on its own. A filing states what changed; it rarely states why, and neither does this page.